 |
 |
 |
# 1133507 © BSIP/B. BOISSONNET | ||
| ||
RIMONABANT
Acomplia is recommanded in the treatment of obesity and Type 2 diabetes. Molecule(s) : Rimonabant. Therapeutic class : selective inhibitor of the type-1 cannabinoid receptors. | ||
| Acomplia | ||
| ||
| ||
| BSIP 34, rue Villiers-de-l'Isle-Adam 75020 Paris international@bsip.com Tel 33-(0)1.43.58.69.87 | ||
|